BioCentury
ARTICLE | Clinical News

GSK's darapladib misses in Phase III ACS trial

May 14, 2014 1:30 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said once-daily oral darapladib ( SB-480848) plus standard of care (SOC) missed the primary endpoint vs. placebo plus SOC in the Phase III SOLID-TIMI 52 trial to treat acute coronary syndrome (ACS). Darapladib plus SOC -- which could include a statin, aspirin and blood pressure medications -- did not improve time to the first occurrence of any component of the composite of coronary heart disease (CHD) death, myocardial infarction (MI) and urgent coronary revascularization for myocardial ischemia vs. placebo plus SOC. The double-blind, international trial enrolled over 13,000 patients who began treatment within 30 days following an ACS. ...